Atypical stress femoral shaft fracture secondary to alendronate therapy
Bisphosphonate (BP) therapy is widely used as it remains the first-line of treatment for osteoporosis. These antiresorptive drugs inhibit osteoclast function and promote apoptosis. However, atypical stress femoral fractures occurring in the diaphysis and subtrochanteric region are linked to prolonge...
Main Authors: | Javier Ardebol, Mario Cahueque, Viriato Mere, Jose Domingo Soto |
---|---|
Format: | Article |
Language: | English |
Published: |
Wolters Kluwer Medknow Publications
2020-01-01
|
Series: | Journal of Orthopedics, Traumatology and Rehabilitation |
Subjects: | |
Online Access: | http://www.jotr.in/article.asp?issn=0975-7341;year=2020;volume=12;issue=1;spage=92;epage=94;aulast=Ardebol |
Similar Items
-
Atypical femoral fracture in the setting of alendronate treatment for osteoporosis: a case report and literature review
by: Eric D. Van Baarsel, et al.
Published: (2019-07-01) -
Bisphosphonate-induced atypical femoral shaft fracture: A case report
by: Ameer Mustafa Farrukh, et al.
Published: (2023-11-01) -
Gene Network of Susceptibility to Atypical Femoral Fractures Related to Bisphosphonate Treatment
by: Natalia Garcia-Giralt, et al.
Published: (2022-01-01) -
Atypical periprosthetic femoral fracture associated with long-term bisphosphonate therapy
by: Dávid Dózsai, et al.
Published: (2020-09-01) -
More Evidence for Teriparatide after Fixation of Atypical Femoral Fractures: Report of Four Cases
by: Lee WC, et al.
Published: (2021-03-01)